Treatment of Vaginal Germ Cell Tumour (Yolk Sac Tumour) in Children and Adolescents with Elevated Serum AFP
Clinical Scenario
This protocol addresses vaginal germ cell tumour — specifically yolk sac tumour (YST) — arising in the paediatric and adolescent population and presenting with elevated serum alpha-foetoprotein (AFP). AFP is the key diagnostic and monitoring marker in this setting and must be measured at diagnosis and throughout treatment.
Key Presenting Features
Vaginal YST is the most common malignant germ cell tumour occurring in the vagina and is frequently associated with elevated serum AFP. The patient's age — childhood or adolescence — is central to treatment planning, directly influencing the selection and intensity of therapy.
Treatment Approach (Partial Overview)
Neoadjuvant chemotherapy, incorporating platinum-based regimens, is the standard first-line approach in this population. The regimen is individualised according to disease extent, dissemination pattern, and the patient's age. Initial surgical resection is not the appropriate first step in this setting — the complete sequencing and drug selection are detailed in the full protocol.
Treatment Goals
The primary objectives are normalisation of serum AFP and achievement of complete remission, confirmed by negative pelvic MRI and negative vaginoscopy.
References
DOI: 10.1016/j.radonc.2023.109662
- Vaginal YST is frequently associated with elevated serum AFP (alpha-foetoprotein), which should always be measured at diagnosis and during treatment.
- YST is by far the most common GCT and the only relevant malignant GCT occurring in the vagina.
- Neoadjuvant chemotherapy is recommended as standard approach [IV, A].
- As a principle, chemotherapy should include platinum derivates regimens. The number of courses, the dose and the used drugs (3 to 4) should be adapted to extent of disease, dissemination pattern and the age of the patient [IV, A].
- At diagnosis, initial tumour resection should always be avoided as vaginal GCT are highly chemo-sensitive [IV, A].
- Tumour biomarker evaluation should include regular measurement of serum AFP [IV, A].
- In case of complete remission after neoadjuvant chemotherapy confirmed by a negative pelvic MRI and negative vaginoscopy and normal AFP, no local treatment is indicated if a strict follow-up is possible [IV, C].
View source ↗